… of ProQR. "We have advanced QR-010 through preclinical development and are looking forward to starting the clinical … its Therapeutic Development Network, a network of CF key opinion leaders, as well as to an extensive clinical trial …
… in mice in vivo via modulation of ANGPLT3 protein properties leading to favorable increase in LPL enzymatic … lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today … the potential of Axiomer EONs in preparation for clinical development and supporting discovery of potential new …
… Research Partnership and EB Medical Research Foundation to Develop QR-313 for the Treatment of Dystrophic Epidermolysis Bullosa The funding will be used for the clinical development of QR-313 Clinical trial in DEB patients to start …
… are no therapies commercially available or in clinical development for this disease. QR-110 has received fast track … granted orphan drug designation in the United States and European Union. Interim safety and efficacy trial results … that the first patient has been dosed in the Phase 1/2 open-label trial assessing the safety, tolerability, …
… lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today … models. “The progress the field and ProQR are making in optimizing ADAR for therapeutic use is exciting,” said Peter … income from partnerships, including the potential Lilly opt-in fee of $50 M for 5 additional targets, milestone …
… European Medicines Agency Grants PRIME Access to ProQR’s … its sepofarsen (QR-110) drug candidate, which is being developed for targeting the p.Cys998X mutation in the CEP290 … been granted access, and only 20% (one out of five) of ophthalmology applications have been granted access. “The …
… Collaboration New agreement supports the discovery and development of additional assets directed toward high … originally announced in September 2021, applied ProQR’s proprietary Axiomer® RNA editing platform to target disorders … additional targets, along with an option for Lilly to opt in for more,” said Daniel A. de Boer, founder and CEO of …
